<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tissue hypoperfusion during <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> results from occlusion of large and small vessels </plain></SENT>
<SENT sid="1" pm="."><plain>Combination treatment strategies using fibrinolytics to thrombolyse an embolic clot and antiplatelet agents to prevent reocclusion and the formation of new platelet <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in the microcirculation may offer advantages over single-agent therapy </plain></SENT>
<SENT sid="2" pm="."><plain>The authors report on the effects of tissue plasminogen activator (rt-PA), a <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (GP) IIb/IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, 7E3 F(ab') 2, or a combination of the two agents in a focal embolic model of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in Wistar rats </plain></SENT>
<SENT sid="3" pm="."><plain>Focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was produced by introducing an autologous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> into the right side middle cerebral artery </plain></SENT>
<SENT sid="4" pm="."><plain>Forty-six male Wistar rats were randomly divided into 6 groups: control (n = 8), 7E3 F(ab') 2 (n = 9, 6 mg/kg), rt-PA (n = 9, 10 mg/kg), rt-PA (n = 6, 20 mg/kg), and 7E3 F(ab') 2 with either 10 mg/kg (n = 10) (low-dose combination) or 20 mg/kg (n = 6) (high-dose combination) rt-PA </plain></SENT>
<SENT sid="5" pm="."><plain>Evaluation of neurobehavioral scores, cerebral angiography, <z:mp ids='MP_0001914'>bleeding</z:mp> time, and measurement of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> volume were used to determine efficacy </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> actively treated groups showed a significant reduction in the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="7" pm="."><plain>Animals treated with 7E3 F(ab') 2 showed reduced infarction volumes (24.0 +/- 5.1%) compared with controls (42.43 +/- 5.6%, P &lt; 0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with rt-PA significantly reduced infarction volume (20.7 +/- 3.3, = 0.01) at 10 mg/kg and at 20 mg/kg (19.5 +/- 8.2%, P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with vehicle-treated animals, the low-dose combination (16.4 +/- 5.5, P &lt; 0.003) and high-dose combination (23.7 +/- 6.2%, P &lt; 0.05) showed significant reduction in infarction volume </plain></SENT>
<SENT sid="10" pm="."><plain>Cerebral angiography revealed significantly better recanalization in the combination group (5/6 animals in the high dose and 4/6 in low dose) compared with animals treated with 7E3 F(ab') 2 (3/10) or rt-PA alone (2/6) </plain></SENT>
<SENT sid="11" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> time significantly increased from 11.25 +/- 1.9 minutes in the control group to 17 +/- 3.1 minutes in the rt-PA group, 24.5 +/- 2.6 minutes in the 7E3 F(ab') 2 group, 25.7 +/- 3.1 minutes in the low-dose combination group, and 32.5 +/- 4.7 minutes in the high-dose combination group </plain></SENT>
<SENT sid="12" pm="."><plain>The incidence of intercerebral <z:mp ids='MP_0001914'>hemorrhage</z:mp> was highest in the high-dose combination group (6 of 6 animals) and lowest in the single treatment with 7E3 F(ab') 2 alone (1 of 10 animals) ( P &lt; 0.05) </plain></SENT>
<SENT sid="13" pm="."><plain>Our data show that murine 7E3 F(ab') 2 alone has therapeutic effects when used after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Although this study suggests that higher doses of thrombolytic combined with anti-GPIIb/IIIa therapy may increases the risk of <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo>, the data also support the notion that anti-GPIIb/IIIa agents can safely be combined with low doses of thrombolytic agent to produce significant attenuation of neuronal damage with no increase in the incidence of <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> </plain></SENT>
</text></document>